NDAINTRAVENOUSPOWDER
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ERAXIS (anidulafungin) by Pfizer is anti-fungal drug [see ]. First approved in 2006.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERAXIS (anidulafungin) is an intravenous echinocandin antifungal approved in 2006 that inhibits fungal cell wall synthesis by targeting beta-glucan. It is indicated for invasive candidiasis and other serious fungal infections in hospitalized patients. The drug works by disrupting fungal cell wall integrity, leading to cell lysis and death.
$0.593MPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending of $593K, the ERAXIS brand team is likely in maintenance mode with minimal growth investment or team expansion anticipated.
Mechanism of Action
anti-fungal drug [see ].
Pharmacologic Class:
Echinocandin Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
Started May 2012
0AspergillosisInvasive Pulmonary AspergillosisNeuroaspergillosis
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
Started Mar 2012
244 enrolled
CandidemiaOther Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
Started Nov 2011
61 enrolled
Liver DiseaseFungal Infection
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
Started Feb 2011
50 enrolled
Candidiasis
A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis
Started Dec 2010
17 enrolled
Candidemia
Worked on ERAXIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.